Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

Market Cap	1.02T +88.4%
Revenue (ttm)	3.52B -76.6%
Net Income	-22.13B
EPS	-235.37
Shares Out	96.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,739,481
Average Volume	2,107,414
Open	12,600
Previous Close	10,990
Day's Range	10,080 - 12,610
52-Week Range	4,325 - 21,500
Beta	n/a
RSI	33.47
Earnings Date	May 21, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body. The company provides Vitabrid C12, a new-conceptual vitamin C product that delivers active vitamin C into the skin. It also develops organic-inorganic hybrid technology, a drug delivery system technology that allows the selective and effective delivery of active substances on the target area in combination with bio-friendly minerals, as well as in anticancer drug carrier technology. The compan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 048410

Financial Performance

In 2025, Hyundai Bioscience's revenue was 3.52 billion, a decrease of -76.63% compared to the previous year's 15.05 billion. Losses were -22.13 billion, 219.3% more than in 2024.